Eli CahanScience’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.For the hundreds of thousands of people enrolling in clinical trials every year—and for whom experimental therapies can offer a last hope—a new report provides some welcome news: Enrollment in clinical studies in the United States is on the rebound after disruptions caused by the COVID-19 pandemic.
But a fresh surge of coronavirus cases could once again scramble studies aimed at testing disease treatments.In June, engagement of new patients in U.S.
clinical trials was down 38% compared with prepandemic levels, found the analysis released last week by the trial tracking firm Medidata.